Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and ...

Imugene continues to actively enrol patients into the Phase 1b azer-cel trial at ten US sites with up to six sites in ...

In a new innovative and groundbreaking medical achievement, Abu Dhabi Stem Cells Centre (ADSCC) has manufactured the UAE's ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The advent of chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has led to improved survival across patient subgroups, according to ...

T-cell lymphoma (TCL) after CART is an extremely rare event and not necessarily related to CAR transgene. Myeloid neoplasm is not rare post-CART, but unclear causality given heavily pretreated patient ...